LXEO Lexeo Therapeutics PE ratio, current and historical analysis

The current PE ratio of LXEO can't be determined, as the TTM EPS of -$3.3 is negative. The last PE ratio of Lexeo Therapeutics, recorded in September 2024, was 0.52.

LXEO PE ratio history

How has LXEO's PE ratio performed in the past

Today

N/A

Average

N/A

Median

N/A

Minimum

N/A

Maximum

N/A

Lexeo Therapeutics PE ratio by year

Year	PE ratio	PE change	Price	EPS
2024	N/A	N/A	$6.58	-$3.09
2023	N/A	N/A	$13.42	-$12.4
2022	N/A	N/A	N/A	-$36.36
2021	N/A	N/A	N/A	-$32.6

Lexeo Therapeutics PE ratio by quarter (TTM)

Year	PE ratio	PE change	Price	EPS
Mar 2025	N/A	N/A	$3.47	-$3.3
Dec 2024	N/A	N/A	$6.58	-$3.09
Sep 2024	0.52	-80.3%	$9.04	$17.54
Jun 2024	2.64	N/A	$16.04	$6.07
Mar 2024	N/A	N/A	$15.68	-$1.59
Dec 2023	N/A	N/A	$13.42	-$12.4
Sep 2023	N/A	N/A	N/A	-$41.1
Jun 2023	N/A	N/A	N/A	-$39.12
Mar 2023	N/A	N/A	N/A	-$40.05
Dec 2022	N/A	N/A	N/A	-$36.36
Sep 2022	N/A	N/A	N/A	N/A
Jun 2022	N/A	N/A	N/A	N/A
Dec 2021	N/A	N/A	N/A	-$32.6

LXEO Price vs fair value

How does LXEO's price compare to its estimated fair value based on its growth

LXEO average PE ratio chart

What is the average PE ratio of LXEO for the past years

3-year avg

N/A

5-year avg

N/A

10-year avg

N/A

15-year avg

N/A

LXEO PE vs peers

What is LXEO's PE ratio compared to its peers

Stock name	PE ratio	Market cap
NTLA Intellia Therapeutics Inc	N/A	$956.07M
CRSP CRISPR Therapeutics AG	N/A	$3.93B
EDIT Editas Medicine Inc	N/A	$175.8M
QURE uniQure NV	N/A	$763.74M
RGNX REGENXBIO Inc	N/A	$394.26M
SGMO Sangamo Therapeutics Inc	N/A	$100.73M
ADVM Adverum Biotechnologies Inc	N/A	$46.59M
BEAM Beam Therapeutics Inc	N/A	$1.68B
VERV Verve Therapeutics Inc	N/A	$990.38M
LXEO Lexeo Therapeutics Inc.	N/A	$131.46M

Frequently asked questions

What is Lexeo Therapeutics's PE ratio?

The current price to earnings ratio of LXEO can't be calculated, as its EPS of -$3.3 is negative.

All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.